Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Clinical trial NCT00574288 · COMPLETED

Trial details

NCT number: NCT00574288
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2008-03-26
Primary completion: 2015-01-09
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.